✦ LIBER ✦

Rate of onset of hypotensive response with oral labetalol [proceedings]

✍ Scribed by AM Breckenridge; CM Macnee; NL Orme; DA Richards; MJ Sterlin

Book ID: 117941456
Publisher: John Wiley and Sons
Year: 1977
Tongue: English
Weight: 156 KB
Volume: 4
Category: Article
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.1977.tb00736.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rate of onset of hypotensive effect of o

Rate of onset of hypotensive effect of oral labetalol.

✍ MJ Serlin; MC Orme; M Maciver; GJ Green; CM Macnee; AM Breckenridge 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 473 KB

Mirtazapine's onset of action compared w

Mirtazapine's onset of action compared with SSRIs: Response and remission rates

✍ H.J.J. Van Oers; A.J. Schutte 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Pathophysiology of post-prandial hypoten

Pathophysiology of post-prandial hypotension in patients with progressive autonomic failure. VI. Comparison of gut peptide responses to oral intake of glucose and protein

✍ Masaaki Hirayama; Toshiaki Ieda; Yasuo Koike; Yuko Takeuchi; Shigeo Takeuchi; No 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 176 KB

Incretin Effect and Glucagon Responses t

Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young--Type 2 and Type 3

✍ Ostoft, S. H.; Bagger, J. I.; Hansen, T.; Pedersen, O.; Holst, J. J.; Knop, F. K 📂 Article 📅 2014 🏛 American Diabetes Association 🌐 English ⚖ 980 KB

Pilot trial of the rate of response, saf

Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors

✍ Mizuhiko Terasaki; Eric Bouffet; Hiroshi Katsuki; Shintaro Fukushima; Minoru Shi 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 174 KB

High rate of clinical complete response

High rate of clinical complete response to weekly outpatient chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin

📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 128 KB